PMC:4608092 / 35919-38459
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4608092","sourcedb":"PMC","sourceid":"4608092","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4608092","text":"Effects of IFN-β on Angiogenic Activity of iPSECs\nWe then investigated effects of IFN-β treatment on tube formation by iPSECs derived from 2 control subjects with the WT RNF213 genotype and 2 MMD patients (homozygous for RNF213 R4810K). Treatment with IFN-β was accompanied by upregulation of RNF213 mRNA expression (Figure3A). Notably, IFN-β treatment lowered tube formation in iPSECs in both of the control subjects and the MMD patients (Figures3B and 4). These data support the notion that IFN-β treatment suppresses angiogenic activity in ECs with induction of RNF213 in humans. In the next step, we investigated the molecular mechanisms of antiangiogenic effects of RNF213.\nFigure 13 Effects of IFN-β on RNF213 protein expression and antiangiogenic activity in iPSECs from control subjects (GG genotype) and MMD patients (AA genotype). A, RNF213 mRNA levels in iPSECs treated with IFN-β for 24 hours. Fold induction attributed to IFN-β was compared with activity at 0 ng/mL of IFN-β. A column with a bar represents mean±SD of 2 controls (blue) or 2 patients (red) in 3 independent experiments. *P\u003c0.05, according to Student t test comparing 0 ng/mL of IFN-β in control (blue) iPSECs at 0.1, 1, or 10 ng/mL. #P\u003c0.05, according to Student t test comparing 0 ng/mL of IFN-β in patient (red) iPSECs at 0.1, 1, or 10 ng/mL. B, Representative photomicrographs (right panel) and quantified tubal area (left panel) of HUVECs and iPSECs treated with IFN-β. Scale bars indicate 100 μm. HUVECs without IFN-β treatment served as the positive control (100%). A column with a bar represents mean±SD of 2 controls or 2 patients in 3 independent experiments. *P\u003c0.05 according to Student t test comparing 0 ng/mL of IFN-β within HUVECs, control iPSECs, or patient iPSECs. HUVECs indicates human umbilical vein endothelial cells; IFN, interferon; iPSECs, induced pluripotent stem cell-derived vascular endothelial cells; MMD, moyamoya disease.\nFigure 14 Tube formation assays for iPSECs after 20 hours of culture on Matrigel with IFN-β. HUVECs without IFN-β treatment served as the control (100%). Total tube length and number of branches were quantified by imaging analysis. A column with a bar represents mean±SD of 2 controls (blue) or 2 patients (red) in 3 independent experiments. *P\u003c0.05, according to Student t test comparing 0 ng/mL of IFN-β within HUVECs, control iPSECs, or patient iPSECs. HUVECs indicates human umbilical vein endothelial cells; IFN, interferon; iPSECs, induced pluripotent stem cell-derived vascular endothelial cells.\n\nL","divisions":[{"label":"Title","span":{"begin":0,"end":49}},{"label":"Figure caption","span":{"begin":679,"end":1934}},{"label":"Figure caption","span":{"begin":1933,"end":2539}}],"tracks":[]}